Jason Mast and Allison DeAngelis

BioTech

Tome Biosciences, once a high-flying gene-editing startup, is floundering

Buzzy gene-editing startup Tome Biosciences is floundering, just nine months after launching with $213 million in funding, according to several sources with direct knowledge of

Jason Mast and Allison DeAngelis August 22, 2024

BioTech

Prime Medicine, Mukherjee’s Myeloid Therapeutics clash over genome-editing deal

The closely watched gene-editing startup Prime Medicine is embroiled in a multimillion-dollar dispute with another biotech it partnered with to develop a potentially powerful new

Jason Mast and Allison DeAngelis December 18, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.

Jason Mast and Allison DeAngelis

Tome Biosciences, once a high-flying gene-editing startup, is floundering

Prime Medicine, Mukherjee’s Myeloid Therapeutics clash over genome-editing deal

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

Subscribe